Ketamine for Depression
Find clinics offering ketamine therapy for treatment-resistant depression (TRD).
Reviewed for clinical accuracy against peer-reviewed literature and FDA guidelines · Last reviewed March 2026
🧠 Ketamine Therapy for Depression: What You Need to Know
Ketamine has emerged as one of the most significant breakthroughs in depression treatment in decades. For patients with treatment-resistant depression (TRD) — defined as failing to respond to two or more adequate antidepressant trials — ketamine offers rapid relief that can begin within hours rather than the weeks required by traditional antidepressants like SSRIs and SNRIs.
Unlike conventional antidepressants that target serotonin or norepinephrine, ketamine works through the glutamate system, the brain's most abundant excitatory neurotransmitter. This novel mechanism allows ketamine to create new neural pathways and restore synaptic connections that depression has weakened or destroyed, essentially helping the brain "rewire" itself.
The FDA's 2019 approval of Spravato (esketamine nasal spray) for treatment-resistant depression marked a milestone in psychiatry, providing the first new mechanism of action for depression treatment in over 30 years. Both IV ketamine infusions and Spravato are now widely available at certified clinics across the United States, giving patients with severe, unresponsive depression a new option when other treatments have failed.
How Ketamine Works for Depression
Ketamine works primarily through NMDA (N-methyl-D-aspartate) receptor antagonism, which triggers a cascade of neurobiological events that rapidly alleviate depressive symptoms. By blocking NMDA receptors, ketamine causes a surge in glutamate release, which activates AMPA receptors and triggers the production of brain-derived neurotrophic factor (BDNF). BDNF is a key protein that promotes the growth and strengthening of synaptic connections in the prefrontal cortex — a brain region critically impaired in depression.
This process, known as synaptogenesis, effectively restores neural connections that have been damaged by chronic depression. While SSRIs and SNRIs slowly modulate serotonin levels over 4-6 weeks, ketamine's glutamate-mediated mechanism can produce measurable improvements in mood within 4 to 24 hours after a single infusion. This rapid onset is particularly valuable for patients in acute crisis or those who cannot wait weeks for traditional antidepressants to take effect.
Clinical Evidence
The landmark 2006 study by Zarate et al. at the National Institute of Mental Health demonstrated that a single IV ketamine infusion produced rapid antidepressant effects in patients with treatment-resistant depression, with 71% of patients responding within 24 hours. Subsequent research has consistently shown response rates of 60-70% for TRD patients receiving ketamine, compared to only 10-30% for patients trying yet another traditional antidepressant. The FDA approved Spravato (esketamine) for TRD in March 2019, based on Phase 3 clinical trials involving over 1,700 patients.
Who Is a Candidate?
The strongest candidates for ketamine therapy for depression are adults who have been diagnosed with treatment-resistant depression, typically defined as failing to achieve adequate relief from at least two different antidepressant medications taken at proper doses for sufficient duration. Ideal candidates include patients experiencing severe functional impairment from depression — difficulty working, maintaining relationships, or performing daily activities — and those who cannot tolerate the side effects of traditional antidepressants. Patients seeking Spravato specifically must have a confirmed TRD diagnosis from their psychiatrist.
Side Effects to Consider
The most common side effects during and shortly after ketamine treatment for depression include dissociation (a feeling of detachment from one's body or surroundings), dizziness, nausea, increased blood pressure, and sedation. These effects are typically mild to moderate and resolve within 1-2 hours after the infusion ends. Patients are monitored in the clinic for at least two hours post-treatment and should not drive for the remainder of the day. Long-term side effect risks of repeated use, including potential bladder and urinary tract effects, are monitored by the treating physician.
Frequently Asked Questions
Common questions about ketamine therapy for treatment-resistant depression (TRD).
How fast does ketamine work for depression?
Many patients experience noticeable improvement in depressive symptoms within 4 to 24 hours after their first ketamine infusion, making it dramatically faster than traditional antidepressants like SSRIs and SNRIs, which typically require 4–6 weeks to take effect. The landmark 2006 study by Zarate et al. at the National Institute of Mental Health found that 71% of patients with treatment-resistant depression responded within 24 hours of a single IV ketamine infusion. A standard initial course consists of six infusions over 2–3 weeks, with many patients feeling significant relief after the second or third treatment. This rapid onset is particularly valuable for patients in acute crisis or those who cannot wait weeks for conventional medications to work. After completing the initial series, maintenance infusions are typically scheduled every 3–6 weeks based on individual symptom recurrence. Discuss your treatment timeline expectations with your clinician so they can set appropriate goals for your recovery.
Is ketamine a cure for depression?
Ketamine is not a cure for depression, but it is a highly effective treatment that can provide rapid and significant relief, especially for treatment-resistant cases where patients have failed 2 or more antidepressant trials. Studies show response rates of 60–70% for treatment-resistant depression, significantly higher than the 10–30% success rate of trying yet another conventional antidepressant. Most patients require ongoing maintenance infusions, typically once every 3–6 weeks, to sustain the benefits over time. The effects of a single infusion generally last 1–3 weeks before symptoms may begin to return. Ketamine is most effective when combined with psychotherapy, regular exercise, and other wellness practices as part of a comprehensive treatment plan rather than being relied upon as a standalone intervention. Talk to your psychiatrist about building a long-term strategy that uses ketamine alongside evidence-based therapies for the most durable outcomes.
How long do ketamine effects last for depression?
The antidepressant effects of a single ketamine infusion typically last between one and three weeks, according to clinical data reviewed in multiple randomized controlled trials including the landmark research by Zarate et al. at the National Institute of Mental Health. With a standard initial series of six infusions administered over 2–3 weeks, many patients experience sustained improvement for several weeks to months as the cumulative neuroplasticity effects build upon each other. Maintenance infusions are usually scheduled based on individual response, with most patients returning every 3–6 weeks to maintain benefits. Some patients find their intervals between maintenance sessions gradually lengthen over time, particularly when ketamine is combined with ongoing psychotherapy. Factors that can affect duration include the severity of your depression, whether you engage in complementary treatments like therapy and exercise, and your individual neurobiology. Work with your provider to track your symptom patterns and optimize your personal maintenance schedule for the longest-lasting relief.
Does insurance cover ketamine for depression?
Insurance coverage for ketamine therapy depends on the specific treatment type. Spravato (esketamine nasal spray), which received FDA approval in 2019, is covered by most major insurance plans including Medicare Part D and many commercial insurers for treatment-resistant depression, though prior authorization and documented failure of at least 2 antidepressants is typically required. Janssen offers a Savings Program that can reduce Spravato copays to $0 for eligible patients with commercial insurance. Traditional IV ketamine infusions are considered off-label for depression and are typically not covered by insurance, with out-of-pocket costs ranging from $400–$800 per infusion or $2,400–$4,800 for the standard 6-session initial series. Some clinics offer financing plans, sliding-scale pricing, or accept HSA and FSA funds to help manage costs. Ask your treatment center about all available payment options and whether they can assist with insurance prior authorization for Spravato before starting treatment.
References
- Zarate CA Jr et al. (2006) Arch Gen Psychiatry. Single IV ketamine infusion produced rapid antidepressant effects within 24 hours in treatment-resistant major depression. [DOI]
- Murrough JW et al. (2013) Am J Psychiatry. Two-site RCT confirmed ketamine produced a greater reduction in depression than midazolam active placebo at 24 hours. [DOI]
- Daly EJ et al. (2018) JAMA Psychiatry. Intranasal esketamine plus oral antidepressant demonstrated significant dose-related improvement in treatment-resistant depression. [DOI]
- Popova V et al. (2019) Am J Psychiatry. Phase 3 TRANSFORM-2 trial supporting FDA Spravato approval showed esketamine nasal spray plus oral antidepressant was superior to antidepressant alone in TRD. [DOI]
Treatment Types for Depression
Explore the different ways ketamine therapy can be administered for treatment-resistant depression (TRD).
IV Ketamine Infusion
Intravenous delivery. Fastest onset, 60-70% response rate. $400-800/session.
Spravato (Esketamine)
FDA-approved nasal spray. Often insurance-covered. $590-885/session.
IM Injection
Intramuscular injection. Similar efficacy, lower cost. $250-500/session.
KAP (Ketamine-Assisted Psychotherapy)
Combines ketamine with guided psychotherapy. $500-1,500/session.